← All trials
NCT04975152
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2026
- First posted
- Jul 23, 2021
- Last posted
- Aug 5, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of South FloridaLead sponsor
- University of South FloridaOverall official - principal investigator
- RegeneronCollaborator
- Sanofi-SynthelaboCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.